Patient‐reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2403-2411

John Wiley & Sons Inc

Access to resources Recommend Favorite

Adjuvant Aromatase Inhibitor Therapy in Patients with Stage I Breast Cancer at a Regional Oncology Center in Israel: Implementation of a ‘Switching' Policy in Postmenopausal Patients after Initial Tamoxifen

By  

Oncology, Vol. 85, Iss. 3, 2013-08 ,pp. : 145-152

Karger

Access to resources Recommend Favorite

Eligibility, Compliance and Persistence of Sequential Therapy with Aromatase Inhibitors following 2–3 Years of Tamoxifen in Endocrine Adjuvant Breast Cancer Therapy

By  

Oncology, Vol. 81, Iss. 3-4, 2011-10 ,pp. : 151-157

Karger

Access to resources Recommend Favorite

Risk of ovarian function recovery should be considered when switching from treatment with adjuvant tamoxifen to aromatase inhibitor therapy in women with chemotherapy‐induced amenorrhea

By  

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 68, Iss. 1, 2018-01 ,pp. : 5-6

John Wiley & Sons Inc

Access to resources Recommend Favorite

Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus

By Pandya Bhavik J.   Bron Morgan   McCall Therese   Yu Andrew P.   Chen Kristina S.   Mattson Miles E.   Wu Eric Q.  

Current Medical Research and Opinion, Vol. 27, Iss. 1, 2011-01 ,pp. : 189-195

Informa Healthcare

Access to resources Recommend Favorite